FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	5	,		

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average I	ourden								
hours nor reenense:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* McCourt Marion (Last) (First) (Middle) 777 OLD SAW MILL RIVER ROAD					<u>RH</u> <u>IN</u>	Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [REGN] Date of Earliest Transaction (Month/Day/Year) 05/02/2022								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) EVP Commercial							
(Street) TARRYTOWN NY 10591 (City) (State) (Zip)					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Tab	le I - No	n-Deriv	ative	Sec	curit	ies Ac	quired,	Dis	sposed o	of, or Be	enefic	ially	Owned	i					
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		ır) E	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)			ies Acquired (A) or Of (D) (Instr. 3, 4 a		and 5) Securiti Benefici Owned		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	(A) or (D) Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
Common Stock				05/02/	/2022				M ⁽¹⁾		1,100	A	\$34	12.93	20,744			D			
Common Stock				05/02/	2/2022				S ⁽¹⁾		1,100	D	\$65	56.97	19,644		D				
Common Stock															116		I 4		By 401(k) Plan		
		Т	able II -								osed of converti				wned						
Derivative Conversion Date Exe Security or Exercise (Month/Day/Year) if a		3A. Deem Execution if any (Month/D	on Date, Tran		ransaction ode (Instr.		n of E		6. Date Exercisabl Expiration Date (Month/Day/Year)		Amount of Securities Underlying Derivative	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amou or Numb of Share	per							
Non- Qualified Stock Option (right to buy)	\$342.93	05/02/2022			M ⁽¹⁾			1,100	(2)		02/12/2028	Common Stock	1,10	00	\$0.0	4,900		D			

Explanation of Responses:

- 1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- 2. The stock option award vests in four equal annual installments, commencing one year after the date of grant.

05/03/2022 /s/** Marion McCourt

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).